NCT00292877View on ClinicalTrials.gov

The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2008

Conditions

Asthma

Interventions

DRUG

SB-240563 (Mepolizumab)

Trial Locations (1)

L8N 4A6

Firestone Institute for Respiratory Health, St. Joseph's Healthcare Hamilton, Hamilton

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

St. Joseph's Healthcare Hamilton

OTHER